M. Oukkal

• PhD
• Head of Department at University Hospital of Beni-Messous, Algiers

Unlabelled: OBJECTIVE: 5-Fluorouracil is a widely used antimetabolite in oncology but can be toxic, particularly in patients with dihydropyrimidine dehydrogenase deficiency. A plasma uracil level exceeding 16 ng/mL and a metabolic ratio (dihydrouracil/uracil) below 6 are indicators of DPD deficiency. This study compares different screening methods...

juvenile polyposis syndrome (JPS) patient; seven (7) germline pathogenic variants and 2 variants of uncertain clinical significance (VUS) in MMR genes. Interestingly, 4 novel germline pathogenic variants in APC gene and 3 novel germline pathogenic variants in MMR genes, respectively, have been detected in our study. The most occurring germline path...

Background: To date, 5% to 6 % of all colorectal cancers (CRCs) areassociated with germline pathogenic variants in cancer predisposition genes that confer inherited predisposition to CRC. The use of genetic testing to identify individuals at risk for hereditary CRC syndromes can help to prevent the development of cancer and in the clinical manageme...

PURPOSE Luminal, human epidermal growth factor receptor 2-negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant strategies of operable breast cancer are mostly based on chemotherapy, whereas it is not completely understood which patients might benefit from neoadjuvant hormone therapy (NAHT). MATERIALS AND MET...

Background The most prevalent subtype of breast cancer (BC) is luminal hormonal-positive breast cancer. The neoadjuvant chemotherapy regimens have side effects, emphasizing the need to identify new startegies. Objective Analyze the complete pathologic response (pCR) rate and overall response in a low-risk hormone-positive subset of patients receiv...

Background: Rat sarcoma virus mutational status guides first-line treatment in metastatic colorectal cancer. This study was a multi center, multi-country ambispective, observational study in the Middle East and North Africa assessing regional rat sarcoma virus testing practices in newly diagnosed patients. Methods: The retrospective arm (2011-20...

Colorectal cancer is the second leading cause of cancer-related deaths in women and men in Algeria. Lynch syndrome (LS) is an autosomal dominant disease caused by heterozygous germline pathogenic variants in mismatch repair genes (MMR) and frequently predisposes to colorectal cancer. However, data about MMR germline pathogenic variants in Algerian...

Colorectal cancer (CRC) is ranked as the third most prevalent and the second deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, the number of CRC cases increased over the past decades and will nearly double by 2030. The lack of clear MENA guidelines for the management of patients with CRC represents a step backwards in t...

596 Background: Luminal, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) encompasses the most common subtype of breast malignancies. Neoadjuvant strategies of operable BC are primarily based upon chemotherapy (CT), while neoadjuvant hormone therapy (NAHT) has not been well studied in the Middle East and North Africa (MEN...

Objective: This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC). Materials and methods: Two-hundred and twenty-th...

PURPOSE Luminal, human epidermal growth factor receptor 2–negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant strategies of operable breast cancer are mostly based on chemotherapy, whereas it is not completely understood which patients might benefit from neoadjuvant hormone therapy (NAHT). MATERIALS AND ME...

BACKGROUND Breast cancer (BC) is a major health issue threatening women's life. No reliable epidemiological data on BC diagnosed by oncologists/senologists are available in Algeria. METHODS The BreCaReAl study, a non-interventional prospective cohort study, included adult women with confirmed BC in Algeria. Disease incidence, patients and disease...

Background: Lung cancer is a major cause of death worldwide. However, few data on incidence, histologic types and mortality rates of lung cancer were available for Algeria. Methods: LuCaReAl is an ongoing descriptive, non-interventional, national, multicenter, prospective and longitudinal study conducted in Algeria, among oncologists and pulmono...

594 Background: While hormonal therapy (HT) is a fundamental treatment in breast cancer therapy, neoadjuvant NAHT is not considered standard. The SAFIA trial is a prospective international neoadjuvant Phase III investigating the potential role of the addition of palbociclib (P) in patients (pts) sensitive to HT. We report the results of induction F...

e16141 Background: RAS testing is essential for treatment selection in metastatic colorectal cancer (mCRC), as anti-EGFR treatment is indicated only in patients with wild-type (WT) RAS. MORE-RAS was a multicenter, multicountry, observational, ambispective (retrospective + prospective) study designed to evaluate RAS mutation status among patients wi...

Le cancer colorectal constitue un problème important de santé publique de par sa fréquence et sa mortalité. Les connaissances sur les facteurs de risque et l’histoire naturelle ont connu des progrès considérables ainsi que le développement de nouveaux moyens de dépistage et de traitement qui vont certainement contribuer à bais-ser à l’avenir, son t...

Background NA chemotherapy (CT) +/- anti-Her2 treatment of operable breast cancer (BC) is considered a standard option in the management of BC. However, pathologic complete response (pCR) rates with CT in HR+/Her2- BC are usually low: 7% (Luminal A) to 16% (Luminal B). Alternatively, NA endocrine therapy (ET) has not been established as a standard...

Background RAS mutational status is an essential criterion to guide first-line treatment in metastatic colorectal cancer (mCRC). MORE-RAS was a multicenter, multicountry, observational, ambispective (retrospective + prospective) study conducted in the Middle East and North Africa (MENA) region to assess RAS testing practices and tumor characteristi...

e12080 Background: Evaluation of the histological response after neoadjuvant chemotherapy with Docetaxel-carboplatin and bio similar Trastuzumab (CANMAB 150mg) in Her2 positive breast cancer. The primary end point was pathologic complete response (pCR) rate, determined from surgical specimens. Methods: Between March 2017 and June 2018, we treated 3...

Background: First-line treatment decisions in patients with mCRC are influenced by biomarker testing. The purpose of the SECURE study is to obtain real-world evidence regarding the decision pathway in first-line treatment selection. Here, we report information concerning biomarker testing practices in the SECURE study. Methods: SECURE is a 2-part,...

L’étude Concord publiée par la revue The lancet oncology en juillet 2008 sur le devenir des maladies oncologiques qui a porté sur 1,9 million de personnes de 31 pays nous a amené à analyser la vulnérabilité du processus de prise en charge médicamenteuse anticancéreuse en Algérie, pays rapporté comme ayant les taux de survie à 5 ans les plus bas de...

Fundamental research identified new therapy targets implicated in tumor proliferation and angiogenesis which lead to the development of several targeted therapies. Currently, three drugs are used in the treatment of advanced colorectal cancer, cetuximab and panitumumab, two anti epidermal growth factor receptor, and bevacizumab, an anti vascular en...

Despite progress in recent years in the treatment of metastatic colorectal cancer (mCCR), mortality remains high. Molecular Targeted Therapy (MTT), against VEGF (Vascular Epidermal Growth Factor) and EGFR (Epidermal Growth Factor Receptor) constitutes a change in digestive cancerology. Patients and methods: 47 Algerian patients average 57 old years...

e15092 Background: Bevacizumab a monoclonal antibody against vascular endothelial growth factor (VEGF) has shown in combination with chemotherapy a significant survival improvement in pts with advanced colorectal cancer (F. Kabbinavar JCO 2005 and H. Hurwitz NEJM 2004). In this study we investigated the safety and the efficacy of the addition of be...